Postoperative Acute Pain Market Size Set for Robust Growth Through 2034

The Postoperative Acute Pain market size is anticipated to grow with a significant CAGR during the study period (2020-2034). DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Postoperative Acute Pain landscape.

The Postoperative Acute Pain market in the United States was estimated at around USD 1,800 million in 2023. Among approved therapies, NSAIDs/Corticosteroids dominated the market, contributing approximately USD 460 million in revenue. Opioids followed closely as the second-largest segment, generating about USD 518 million in the same year. With the anticipated approval of several emerging therapies, the market is expected to witness significant growth during the forecast period from 2024 to 2034.

In 2023, the United States recorded approximately 58.7 million surgery-related visits, with inpatient procedures accounting for a larger share than outpatient ones. Across the 7MM, moderate postoperative acute pain represented the highest proportion of cases at around 45%, followed by severe and mild categories. Additionally, the total number of incident postoperative acute pain cases in the US was estimated at nearly 47 million in 2023.

DelveInsight’s report, “Postoperative Acute Pain Market Insights, Epidemiology, and Market Forecast-2034” provides a comprehensive analysis of the Postoperative Acute Pain landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Postoperative Acute Pain market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Postoperative Acute Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Postoperative Acute Pain Market Forecast

Some of the key facts of the Postoperative Acute Pain Market Report:

• The US market for Postoperative Acute Pain includes therapies such as LICART, UBRELVY, REYVOW, NURTEC ODT, and others
• NSAIDs offer anti-inflammatory, antipyretic, analgesic, and antithrombotic effects by inhibiting cyclooxygenase enzymes COX-1 and COX-2. The availability of multiple generics in the market is primarily due to patent expirations.
• Key Postoperative Acute Pain Companies: Pacira BioSciences, AcelRx Pharmaceuticals, Oculis, Vertex Pharmaceuticals, Scilex Holding, Pfizer, Biohaven, H. Lundbeck A/S. Axsome Therapeutics, and other
• Key Postoperative Acute Pain Therapies: EXPAREL (bupivacaine liposome injectable suspension), DSUVIA (sufentanil), OCS-01 (dexamethasone cyclodextrin nanoparticle ophthalmic suspension 1.5%), VX-548, ELYXYB (celecoxib), ZAVZPRET (zavegepant), NURTEC ODT, VYEPTI (eptinezumab), AXS-07, and others
• The Postoperative Acute Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Postoperative Acute Pain pipeline products will significantly revolutionize the Postoperative Acute Pain market dynamics.
• In 2023, type-specific incident cases of Postoperative Acute Pain in the United States were distributed as approximately 60% for trauma-related pain and 40% for other causes.
• In the United States, severity-specific incident cases of Postoperative Acute Pain were highest for moderate pain, totaling approximately 25 million cases in 2023.
• In the seven major markets, moderate to severe cases accounted for approximately 60% of the total diagnosed cases in 2023.

Postoperative Acute Pain Overview

Postoperative acute pain is the immediate pain experienced by patients following a surgical procedure, typically lasting from a few hours to several days. It results from tissue injury, inflammation, and nerve stimulation caused during surgery. The intensity and duration of pain can vary depending on the type of surgery, patient health, and individual pain tolerance.

Get a Free sample for the Postoperative Acute Pain Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/post-operative-acute-pain-market

Key Trends in Postoperative Acute Pain Therapeutics Market:

• Shift toward non-opioid pain management solutions: Growing concerns over opioid dependency and side effects are accelerating the adoption of non-opioid alternatives such as NSAIDs, local anesthetics, and novel analgesics.
• Rising adoption of multimodal analgesia approaches: Combination therapies using multiple drug classes are increasingly preferred to enhance pain relief while minimizing opioid dosage and associated risks.
• Advancements in drug delivery technologies: Innovations such as extended-release formulations, transdermal systems, and targeted delivery methods are improving treatment efficacy and patient compliance.
• Emergence of personalized pain management strategies: Tailored therapies based on patient-specific factors (genetics, comorbidities, pain sensitivity) are gaining traction to optimize outcomes and reduce adverse effects.
• Integration of enhanced recovery protocols and clinical guidelines: Increasing adoption of evidence-based recovery pathways and structured pain management protocols is driving demand for advanced therapeutics.

Postoperative Acute Pain Epidemiology

The Postoperative Acute Paiepidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Postoperative Acute Pain Epidemiology Segmentation:

The Postoperative Acute Pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Postoperative Acute Pain
• Prevalent Cases of Postoperative Acute Pain by severity
• Gender-specific Prevalence of Postoperative Acute Pain
• Diagnosed Cases of Episodic and Chronic Postoperative Acute Pain

Download the report to understand which factors are driving Postoperative Acute Pain epidemiology trends @ Postoperative Acute Pain Epidemiology Forecast

Recent Development In The Postoperative Acute Pain Treatment Landscape:

• In 2025, the US FDA approved three new therapies for the acute treatment of migraine in patients with moderate-to-severe pain: ATZUMI (dihydroergotamine mesylate), SYMBRAVO (a combination of meloxicam and rizatriptan), and BREKIYA (dihydroergotamine mesylate) from Amneal Pharmaceuticals. Meanwhile, QUTENZA (capsaicin) 8% topical system is anticipated to release topline results in Q4 2025, with Averitas Pharma planning to submit a supplemental New Drug Application (sNDA) in 2026, subject to positive findings.
• In May 2025, Tris Pharma announced that data on cebranopadol were showcased in three poster presentations at the 50th Annual Regional Anesthesiology and Acute Pain Medicine (ASRA) meeting.
• In April 2025, The US FDA approved ATZUMI (dihydroergotamine) nasal powder for the acute treatment of migraine in adults, both with and without aura.
• In March 2025, Latigo Biotherapeutics announced that the US FDA has granted Fast Track Designation (FTD) to LTG-001, its investigational oral selective Nav1.8 inhibitor for acute pain treatment. This designation follows encouraging Phase I results that showed favorable safety, tolerability, and pharmacokinetic properties for LTG-001.
• In January 2025, Axsome Therapeutics announced that the US Food and Drug Administration has approved SYMBRAVO (a combination of meloxicam and rizatriptan) for the acute treatment of migraine in adults, both with and without aura.

Postoperative Acute Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Postoperative Acute Pain market or expected to get launched during the study period. The analysis covers Postoperative Acute Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Postoperative Acute Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Postoperative Acute Pain Therapies and Key Companies

• EXPAREL (bupivacaine liposome injectable suspension): Pacira BioSciences
• DSUVIA (sufentanil): AcelRx Pharmaceuticals
• OCS-01 (dexamethasone cyclodextrin nanoparticle ophthalmic suspension 1.5%): Oculis
• VX-548: Vertex Pharmaceuticals
• ELYXYB (celecoxib): Scilex Holding
• ZAVZPRET (zavegepant): Pfizer
• NURTEC ODT: Pfizer/Biohaven
• VYEPTI (eptinezumab): H. Lundbeck A/S
• AXS-07: Axsome Therapeutics

Discover more about therapies set to grab major Postoperative Acute Pain market share @ Postoperative Acute Pain Treatment Landscape

Postoperative Acute Pain Market Drivers

• Rising Surgical Procedures: Increasing volume of elective and emergency surgeries globally is driving demand for effective postoperative pain management.
• Growing Focus on Patient-Centric Care: Emphasis on improved recovery outcomes and patient satisfaction is boosting adoption of advanced pain management solutions.
• Advancements in Analgesic Therapies: Development of novel non-opioid analgesics, extended-release formulations, and multimodal pain management approaches is enhancing treatment efficacy.
• Shift Toward Opioid-Sparing Strategies: Rising concerns over opioid dependency are accelerating the use of alternative pain therapies.
• Improved Healthcare Infrastructure: Expansion of hospitals and ambulatory surgical centers is supporting greater access to postoperative care.

Postoperative Acute Pain Market Barriers

• Opioid-Related Risks and Regulations: Strict regulatory controls and safety concerns around opioids can limit their use and complicate pain management strategies.
• Limited Efficacy of Current Alternatives: Some non-opioid treatments may not provide sufficient pain relief for all patients.
• High Cost of Advanced Therapies: Innovative pain management solutions and delivery systems can be expensive, affecting adoption.
• Variability in Pain Perception: Differences in patient response to pain and treatment make standardized care challenging.
• Risk of Adverse Effects: Side effects associated with analgesics, including NSAIDs and opioids, may limit their long-term use.

Scope of the Postoperative Acute Pain Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Postoperative Acute Pain Companies: Pacira BioSciences, AcelRx Pharmaceuticals, Oculis, Vertex Pharmaceuticals, Scilex Holding, Pfizer, Biohaven, H. Lundbeck A/S. Axsome Therapeutics, and others
• Key Postoperative Acute Pain Therapies: EXPAREL (bupivacaine liposome injectable suspension), DSUVIA (sufentanil), OCS-01 (dexamethasone cyclodextrin nanoparticle ophthalmic suspension 1.5%), VX-548, ELYXYB (celecoxib), ZAVZPRET (zavegepant), NURTEC ODT, VYEPTI (eptinezumab), AXS-07, and others
• Postoperative Acute Pain Therapeutic Assessment: Postoperative Acute Pain current marketed and Postoperative Acute Pain emerging therapies
• Postoperative Acute Pain Market Dynamics: Postoperative Acute Pain market drivers and Postoperative Acute Pain market barriers 
• Postoperative Acute Pain Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Postoperative Acute Pain Unmet Needs, KOL’s views, Analyst’s views, Postoperative Acute Pain Market Access and Reimbursement

To know more about Postoperative Acute Pain companies working in the treatment market, visit @ Postoperative Acute Pain Clinical Trials and Therapeutic Assessment

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.